Wei Gan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Wei Gan has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
Bin Feng
Sichuan University, West China Clinical Medical College, Chengdu, Sichuan Province, China
3 shared publicationsShanshan Liang
Department of Laboratory Medicine, West China Hospital, Sichuan University
3 shared publications- Chuanmin Tao
Department of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu, China
2 shared publications He Zhang
Department of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu, 610041, China
2 shared publicationsRuyi Zhou
Department of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu 610041, China
2 shared publicationsShuyu Yang
Department of Laboratory Medicine, West China Hospital, Sichuan University
2 shared publications
Latest Publications
- 5 November 2026
- Published by Taylor & Francis in Scandinavian Journal of Clinical and Laboratory Investigation
- p. 1-15
Triglyceride-dependent discordance in routine LDL cholesterol reporting during postprandial lipaemia: a self-controlled repeated-measures study
Low-density lipoprotein cholesterol (LDL-C) is a well-established causal risk factor for atherosclerotic cardiovascular disease (ASCVD) and remains the primary treatment target in major lipid-manag...
- 5 November 2026
- Published by Taylor & Francis in Scandinavian Journal of Clinical and Laboratory Investigation
- p. 1-15
Triglyceride-dependent discordance in routine LDL cholesterol reporting during postprandial lipaemia: a self-controlled repeated-measures study
Low-density lipoprotein cholesterol (LDL-C) is a well-established causal risk factor for atherosclerotic cardiovascular disease (ASCVD) and remains the primary treatment target in major lipid-manag...
- 10 October 2026
- Published by Springer Nature in Endocrine
- Vol. 91 (1) , 342
Dynamic transitions from prediabetes to diabetes and incident cardiovascular events in middle-aged and older chinese adults: a nationwide longitudinal study
- 10 October 2026
- Published by Springer Nature in Endocrine
- Vol. 91 (1) , 342
Dynamic transitions from prediabetes to diabetes and incident cardiovascular events in middle-aged and older chinese adults: a nationwide longitudinal study
- 1 March 2026
- Published by Elsevier in Analytica Chimica Acta
- Vol. 1400, 345316
Dual-layer N-glycoproteomics enhances resolution of serum glycosylation signatures in type 2 diabetes mellitus complicated with coronary heart disease
- 1 March 2026
- Published by Elsevier in Analytica Chimica Acta
- Vol. 1400, 345316
Dual-layer N-glycoproteomics enhances resolution of serum glycosylation signatures in type 2 diabetes mellitus complicated with coronary heart disease
- Open Access
- 15 February 2026
- Published by Croatian Society for Medical Biochemistry and Laboratory Medicine in Biochemia Medica
- Vol. 36 (1) , 142-149
Falsely decreased triglyceride concentration in a patient with acute pancreatitis due to insufficient configuration of alarm rules
Acute pancreatitis is a potentially life-threatening complication of severe hypertriglyceridemia. The accurate measurement of triglyceride concentration is essential for diagnosis and therapeutic monitoring. This article presents a case of acute hypertriglyceridemia pancreatitis in which the patient’s triglyceride concentration appeared to drop rapidly from 128.04 mmol/L to 1.53 mmol/L within 12 hours of admission. Subsequent retesting revealed an actual triglyceride value of 88.92 mmol/L. This case underscores a critical and underreported preanalytical challenge: the failure of the analyzer to trigger “> Kin” warnings despite clear abnormalities in the reaction kinetics curve, leading to clinically significant underestimation. To mitigate such errors, we propose a novel strategy that integrates automated lipemic index-based predilution protocols with enhanced alarm configurations, including the introduction of a “>Abs” alert, adjustment of prozone detection parameters, and the implementation of correlation checks between lipemic indices and triglyceride values within the laboratory information system. These practical interventions, which can be adopted in clinical laboratories, represent a proactive approach to prevent erroneous reporting and enhance diagnostic reliability. This report highlights the necessity for increased vigilance among laboratory professionals when discordance occurs between high lipemic indices and unexpectedly low triglyceride results, suggesting possible kinetic anomalies.
- 15 February 2026
- Published by Croatian Society for Medical Biochemistry and Laboratory Medicine in Biochemia Medica
- Vol. 36 (1) , 142-149
Open AccessFalsely decreased triglyceride concentration in a patient with acute pancreatitis due to insufficient configuration of alarm rules
Acute pancreatitis is a potentially life-threatening complication of severe hypertriglyceridemia. The accurate measurement of triglyceride concentration is essential for diagnosis and therapeutic monitoring. This article presents a case of acute hypertriglyceridemia pancreatitis in which the patient’s triglyceride concentration appeared to drop rapidly from 128.04 mmol/L to 1.53 mmol/L within 12 hours of admission. Subsequent retesting revealed an actual triglyceride value of 88.92 mmol/L. This case underscores a critical and underreported preanalytical challenge: the failure of the analyzer to trigger “> Kin” warnings despite clear abnormalities in the reaction kinetics curve, leading to clinically significant underestimation. To mitigate such errors, we propose a novel strategy that integrates automated lipemic index-based predilution protocols with enhanced alarm configurations, including the introduction of a “>Abs” alert, adjustment of prozone detection parameters, and the implementation of correlation checks between lipemic indices and triglyceride values within the laboratory information system. These practical interventions, which can be adopted in clinical laboratories, represent a proactive approach to prevent erroneous reporting and enhance diagnostic reliability. This report highlights the necessity for increased vigilance among laboratory professionals when discordance occurs between high lipemic indices and unexpectedly low triglyceride results, suggesting possible kinetic anomalies.
- Open Access
- 27 November 2025
- Published by Baishideng Publishing Group Inc. in World Journal of Hepatology
- Vol. 17 (11)
Non-invasive blood biomarkers for assessment of liver fibrosis in metabolic dysfunction-associated steatotic liver disease
Metabolic dysfunction-associated steatotic liver disease (MASLD) requires accurate liver fibrosis assessment for management. While liver biopsy remains the gold standard, its invasiveness drives demand for non-invasive biomarkers. This review evaluates blood biomarkers for MASLD fibrosis staging. Established scores (fibrosis-4, non-alcoholic fatty liver disease fibrosis score) offer accessible screening but exhibit variable performance influenced by age, obesity, and comorbidities. Patented panels (e.g. , enhanced liver fibrosis test, FibroMeter) improve accuracy by integrating extracellular matrix or metabolic markers, though context-specific thresholds are essential. Emerging biomarkers like propeptide of type 3 collagen, Mac-2 binding protein glycosylation isomer, epigenetic markers (proliferator-activated receptor-γ methylation), and angiopoietin-like proteins a family of eight glycoproteins show promise but require large-scale validation. Genetic risk scores and multi-omics approaches face generalizability challenges. Integration strategies, such as combining serum biomarkers with liver stiffness measurement via Agile scores, enhance diagnostic precision and reduce indeterminate classifications. Current tools aid risk stratification, but no single biomarker replicates biopsy-level precision. Future efforts must prioritize MASLD-specific diagnostic frameworks, standardized protocols, and multi-modal integration to enhance clinical utility and address MASLD’s growing burden.
- 27 November 2025
- Published by Baishideng Publishing Group Inc. in World Journal of Hepatology
- Vol. 17 (11)
Open AccessNon-invasive blood biomarkers for assessment of liver fibrosis in metabolic dysfunction-associated steatotic liver disease
Metabolic dysfunction-associated steatotic liver disease (MASLD) requires accurate liver fibrosis assessment for management. While liver biopsy remains the gold standard, its invasiveness drives demand for non-invasive biomarkers. This review evaluates blood biomarkers for MASLD fibrosis staging. Established scores (fibrosis-4, non-alcoholic fatty liver disease fibrosis score) offer accessible screening but exhibit variable performance influenced by age, obesity, and comorbidities. Patented panels (e.g. , enhanced liver fibrosis test, FibroMeter) improve accuracy by integrating extracellular matrix or metabolic markers, though context-specific thresholds are essential. Emerging biomarkers like propeptide of type 3 collagen, Mac-2 binding protein glycosylation isomer, epigenetic markers (proliferator-activated receptor-γ methylation), and angiopoietin-like proteins a family of eight glycoproteins show promise but require large-scale validation. Genetic risk scores and multi-omics approaches face generalizability challenges. Integration strategies, such as combining serum biomarkers with liver stiffness measurement via Agile scores, enhance diagnostic precision and reduce indeterminate classifications. Current tools aid risk stratification, but no single biomarker replicates biopsy-level precision. Future efforts must prioritize MASLD-specific diagnostic frameworks, standardized protocols, and multi-modal integration to enhance clinical utility and address MASLD’s growing burden.
- Open Access
- 1 July 2025
- Published by Springer Nature in Lipids in Health and Disease
- Vol. 24 (1) , 1-10
Lipoprotein trajectories from prediabetes to type 2 diabetes with complications: a Chinese population-specific formula for sdLDL-C estimation
This study aimed to (1) evaluate small dense low-density lipoprotein cholesterol (sdLDL-C) dynamics from prediabetes to type 2 diabetes mellitus (T2DM) with complications, (2) validate existing sdLDL-C estimation formulas (Sampson’s, Srisawasdi’s, Han’s) in Chinese populations, and (3) develop a population-specific formula for enhanced accuracy. A multicenter study recruited 1,944 participants (216 controls, 70 with prediabetes, 212 with newly diagnosed T2DM, 164 with treated T2DM, and 1,286 in validation cohorts). Lipid profiles, including sdLDL-C (measured via enzymatic assays), were analyzed. Formula performance was assessed using spearman correlation, intraclass correlation coefficients (ICC), and multivariable linear regression. A novel formula was derived via multivariable regression. Atherogenic lipid triad manifestations emerged early: sdLDL-C was significantly elevated in participants with prediabetes (1.07 [0.73, 1.40] vs. 0.57 [0.44, 0.72] mmol/L in controls, P < 0.05) and further increased in those with T2DM, correlating strongly with triglycerides (TG; r = 0.59), non-high-density lipoprotein cholesterol (nonHDL-C; r = 0.69), and apolipoprotein B (ApoB; r = 0.62). Existing formulas overestimated sdLDL-C in controls and treated T2DM (P < 0.05), though both Han’s and Sampson’s formula performed better in newly diagnosed T2DM (P > 0.05). A novel sdLDL-C estimation formula, incorporating low-density lipoprotein cholesterol (LDL-C), TG, nonHDL-C, age, and sex, achieved superior accuracy (R²=0.743; ICC = 0.681) and minimized residuals (Δ = 0.16 vs. 0.28–0.29, P < 0.05). sdLDL-C elevation begins in prediabetes, highlighting its value for early atherosclerotic cardiovascular disease (ASCVD) risk assessment. Current formulas show population-specific limitations, whereas the new model provides improved accuracy for Chinese T2DM patients, enabling cost-effective sdLDL-C estimation and personalized lipid management.
- 1 July 2025
- Published by Springer Nature in Lipids in Health and Disease
- Vol. 24 (1) , 1-10
Open AccessLipoprotein trajectories from prediabetes to type 2 diabetes with complications: a Chinese population-specific formula for sdLDL-C estimation
This study aimed to (1) evaluate small dense low-density lipoprotein cholesterol (sdLDL-C) dynamics from prediabetes to type 2 diabetes mellitus (T2DM) with complications, (2) validate existing sdLDL-C estimation formulas (Sampson’s, Srisawasdi’s, Han’s) in Chinese populations, and (3) develop a population-specific formula for enhanced accuracy. A multicenter study recruited 1,944 participants (216 controls, 70 with prediabetes, 212 with newly diagnosed T2DM, 164 with treated T2DM, and 1,286 in validation cohorts). Lipid profiles, including sdLDL-C (measured via enzymatic assays), were analyzed. Formula performance was assessed using spearman correlation, intraclass correlation coefficients (ICC), and multivariable linear regression. A novel formula was derived via multivariable regression. Atherogenic lipid triad manifestations emerged early: sdLDL-C was significantly elevated in participants with prediabetes (1.07 [0.73, 1.40] vs. 0.57 [0.44, 0.72] mmol/L in controls, P < 0.05) and further increased in those with T2DM, correlating strongly with triglycerides (TG; r = 0.59), non-high-density lipoprotein cholesterol (nonHDL-C; r = 0.69), and apolipoprotein B (ApoB; r = 0.62). Existing formulas overestimated sdLDL-C in controls and treated T2DM (P < 0.05), though both Han’s and Sampson’s formula performed better in newly diagnosed T2DM (P > 0.05). A novel sdLDL-C estimation formula, incorporating low-density lipoprotein cholesterol (LDL-C), TG, nonHDL-C, age, and sex, achieved superior accuracy (R²=0.743; ICC = 0.681) and minimized residuals (Δ = 0.16 vs. 0.28–0.29, P < 0.05). sdLDL-C elevation begins in prediabetes, highlighting its value for early atherosclerotic cardiovascular disease (ASCVD) risk assessment. Current formulas show population-specific limitations, whereas the new model provides improved accuracy for Chinese T2DM patients, enabling cost-effective sdLDL-C estimation and personalized lipid management.
- 18 February 2025
- Published by Elsevier in Clinica Chimica Acta
- Vol. 570, 120206
Proatherogenic changes in the quantity and quality of lipoproteins in adults with idiopathic nephrotic syndrome
- 18 February 2025
- Published by Elsevier in Clinica Chimica Acta
- Vol. 570, 120206
Proatherogenic changes in the quantity and quality of lipoproteins in adults with idiopathic nephrotic syndrome
- Open Access
- 6 September 2024
- Published by Taylor & Francis in Annals of Medicine
- Vol. 56 (1) , 2400312
Establishment and validation of a prognostic model based on common laboratory indicators for SARS-CoV-2 infection in Chinese population
At the beginning of December 2022, the Chinese government made major adjustments to the epidemic prevention and control measures. The epidemic infection data and laboratory makers for infected patients based on this period may help with the management and prognostication of COVID-19 patients. The COVID-19 patients hospitalized during December 2022 were enrolled. Logistic regression analysis was used to screen significant factors associated with mortality in patients with COVID-19. Candidate variables were screened by LASSO and stepwise logistic regression methods and were used to construct logistic regression as the prognostic model. The performance of the models was evaluated by discrimination, calibration, and net benefit. 888 patients were eligible, consisting of 715 survivors and 173 all-cause deaths. Factors significantly associated with mortality in COVID-19 patients were: lactate dehydrogenase (LDH), albumin (ALB), procalcitonin (PCT), age, smoking history, malignancy history, high density lipoprotein cholesterol (HDL-C), lactate, vaccine status and urea. 335 of the 888 eligible patients were defined as ICU cases. Seven predictors, including neutrophil to lymphocyte ratio, D-dimer, PCT, C-reactive protein, ALB, bicarbonate, and LDH, were finally selected to establish the prognostic model and generate a nomogram. The area under the curve of the receiver operating curve in the training and validation cohorts were respectively 0.842 and 0.853. In terms of calibration, predicted probabilities and observed proportions displayed high agreements. Decision curve analysis showed high clinical net benefit in the risk threshold of 0.10-0.85. A cutoff value of 81.220 was determined to predict the outcome of COVID-19 patients via this nomogram. The laboratory model established in this study showed high discrimination, calibration, and net benefit. It may be used for early identification of severe patients with COVID-19.
- 6 September 2024
- Published by Taylor & Francis in Annals of Medicine
- Vol. 56 (1) , 2400312
Open AccessEstablishment and validation of a prognostic model based on common laboratory indicators for SARS-CoV-2 infection in Chinese population
At the beginning of December 2022, the Chinese government made major adjustments to the epidemic prevention and control measures. The epidemic infection data and laboratory makers for infected patients based on this period may help with the management and prognostication of COVID-19 patients. The COVID-19 patients hospitalized during December 2022 were enrolled. Logistic regression analysis was used to screen significant factors associated with mortality in patients with COVID-19. Candidate variables were screened by LASSO and stepwise logistic regression methods and were used to construct logistic regression as the prognostic model. The performance of the models was evaluated by discrimination, calibration, and net benefit. 888 patients were eligible, consisting of 715 survivors and 173 all-cause deaths. Factors significantly associated with mortality in COVID-19 patients were: lactate dehydrogenase (LDH), albumin (ALB), procalcitonin (PCT), age, smoking history, malignancy history, high density lipoprotein cholesterol (HDL-C), lactate, vaccine status and urea. 335 of the 888 eligible patients were defined as ICU cases. Seven predictors, including neutrophil to lymphocyte ratio, D-dimer, PCT, C-reactive protein, ALB, bicarbonate, and LDH, were finally selected to establish the prognostic model and generate a nomogram. The area under the curve of the receiver operating curve in the training and validation cohorts were respectively 0.842 and 0.853. In terms of calibration, predicted probabilities and observed proportions displayed high agreements. Decision curve analysis showed high clinical net benefit in the risk threshold of 0.10-0.85. A cutoff value of 81.220 was determined to predict the outcome of COVID-19 patients via this nomogram. The laboratory model established in this study showed high discrimination, calibration, and net benefit. It may be used for early identification of severe patients with COVID-19.
- 5 August 2024
- Published by Elsevier in Clinica Chimica Acta
- Vol. 563, 119900
Spurious dyslipidemia due to paraprotein in a patient with Waldenström macroglobulinemia
- 5 August 2024
- Published by Elsevier in Clinica Chimica Acta
- Vol. 563, 119900
Spurious dyslipidemia due to paraprotein in a patient with Waldenström macroglobulinemia
- 26 August 2023
- Published by Elsevier in Clinica Chimica Acta
- Vol. 548, 117529
The necessity for improving lipid testing reagents: A real world study
- 26 August 2023
- Published by Elsevier in Clinica Chimica Acta
- Vol. 548, 117529
The necessity for improving lipid testing reagents: A real world study